DUBLIN (AP) _ Jazz Pharmaceuticals PLC (JAZZ) on Tuesday reported third-quarter earnings of $102.3 million.
On a per-share basis, the Dublin-based company said it had net income of $1.78. Earnings, adjusted for one-time gains and costs, were $4.10 per share.
The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $3.59 per share.
The drugmaker posted revenue of $537.7 million in the period, also topping Street forecasts. Seven analysts surveyed by Zacks expected $522.7 million.
Jazz expects full-year earnings in the range of $15.50 to $16.15 per share, with revenue in the range of $2.1 billion to $2.18 billion.
Jazz shares have risen 3% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $127.80, a fall of 21% in the last 12 months.